Table 2. Clinical profile of concurrent gene alterations in non-small cell lung cancer patients.

Case	Gender	Age	Smoking history	Histology	Gene type	EGFR-TKI/which line	Response	PFS/month	OS/month
1	Male	44	Yes	Adenocarcinoma	19del+PIK3CA	Gefitinib/Second	PR	10.4	18.7
2	Male	75	No	Adenocarcinoma	19del+PIK3CA	Icotinib/Third	PR	11.2	20.3
3	Female	62	No	Adenocarcinoma	L861Q+PIK3CA	Icotinib/Second	PD	1.2	12.5
4	Male	59	Yes	Adenocarcinoma	19del+PIK3CA	Icotinib/Third	PR	7.6	17.6
5	Female	75	No	Adenocarcinoma	19del+PIK3CA	Gefitinib/Third	PR	6	15.5
6	Male	62	No	Adenocarcinoma	L858R+PIK3CA	Icotinib/Second	SD	9.5	16.7
7	Male	67	Yes	Adenosquamous	19del+PIK3CA	Icotinib/Third	PR	9.7	20.5
8	Female	66	No	Adenocarcinoma	G719X+PIK3CA	Icotinib/Second	PD	2	12.1
9	Male	44	Yes	Adenocarcinoma	19del+PIK3CA	Gefitinib/Second	PR	7.5	17.6
10	Female	64	No	Adenocarcinoma	L858R+ALK	Gefitinib/First	SD	4.5	16.5
11	Female	40	No	Adenocarcinoma	19del+ALK	Icotinib/Second	PR	8.9	24.3+
12	Male	64	No	Adenocarcinoma	19del+ALK	Erlotinib/First	PR	14	28.7
13	Female	59	No	Adenocarcinoma	19del+ALK	Icotinib/Third	PD	1.2	19.5
14	Male	45	No	Adenocarcinoma	19del+ALK	Erlotinib/First	SD	5	18.6
15	Male	64	Yes	Adenocarcinoma	19del+ALK	Icotinib/Second	SD	6.5	17.7
16	Female	65	No	Adenocarcinoma	19del++HER2	Icotinib/Third	PD	1.2	12.5
17	Female	69	No	Adenocarcinoma	L861Q+HER2	Icotinib/Second	PD	1	6.5
18	Female	50	No	Adenocarcinoma	19del+HER2	Icotinib/Second	PR	14.4	17.7
19	Female	60	No	Adenocarcinoma	L858R+RET	Gefitinib/Third	PD	2.2	10.2
20	Male	63	Yes	Adenocarcinoma	L858R+KRAS	Erlotinib/First	PD	1	6.5
21	Male	49	Yes	Adenocarcinoma	19del+ROS1	Erlotinib/First	PR	24	47.8+